OptimizeRx Corp. (NASDAQ: OPRX), a healthcare technology company providing digital solutions for life sciences, announced it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility comprises a $25 million term loan and a $10 million revolving credit facility, which was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction.
This new credit facility strengthens OptimizeRx's balance sheet and provides additional liquidity to support its growth strategy, which includes expanding its AI-driven platform and enhancing its offerings for pharmaceutical and life sciences clients. The company’s platform combines innovative tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between healthcare provider and direct-to-consumer strategies, OptimizeRx empowers brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
The announcement underscores OptimizeRx's commitment to patient-centric technology and its ability to secure favorable financing terms in a challenging economic environment. The credit facility provides financial flexibility to pursue strategic acquisitions, invest in research and development, and support working capital needs. For more details, visit the full announcement at https://ibn.fm/G0Fj3.
OptimizeRx is headquartered in Waltham, Massachusetts, and partners with some of the world’s leading pharmaceutical and life sciences companies. The company’s platform is designed to deliver life-changing therapies to the right patients at the right time, leveraging privacy-safe technology. Additional information about OptimizeRx can be found at www.optimizerx.com.
This credit facility comes at a time when OptimizeRx continues to innovate within the healthcare technology space, aiming to transform how life science brands connect with patients and healthcare providers. The funding is expected to accelerate the adoption of its AI-driven tools and expand its market reach. As the company executes its growth plan, the new credit line provides a solid capital base to navigate the evolving healthcare landscape.
